GSK
Visit at https://www.gsk.com/en-gb/home/
GSK
GSK plc is a British multinational pharmaceutical and biotechnology company focused on developing treatments in areas such as respiratory, immunology, oncology, HIV, and infectious diseases. It aims to positively impact the health of 2.5 billion people by the end of the decade.
Positive signals
GSK has set a target to use 100% renewable electricity across its global operations by 2025, further supporting its decarbonization strategy.
Between 2019 and 2020, GSK reduced its carbon emissions by 34%, waste to landfill by 78%, and total water use by 31%, demonstrating significant progress toward its environmental goals.
GSK’s net zero target for 2045 has been approved by the Science Based Targets initiative (SBTi), making it one of the few pharmaceutical companies with a validated net zero pathway in line with the SBTi Corporate Net-Zero Standard.
GSK is testing an alternative propellant for inhalers that could reduce greenhouse gas emissions from these products by approximately 90% if successful, addressing a significant source of pharmaceutical sector emissions.
GSK has committed to an 80% absolute reduction in greenhouse gas emissions across all scopes by 2030 (from a 2020 baseline), with the remaining 20% to be addressed through investment in nature-based solutions.
Concerns
GSK has faced criticism and legal scrutiny in the past for product safety issues, including high-profile lawsuits related to the side effects of its pharmaceutical products, which have resulted in significant financial penalties and reputational damage.
HIGH
Source →
